Skip to content

Effect of Vitamin D on Crestal Bone Loss Around Immediate Implant After Mandibular Premolars and Molars Extraction

Clinical and Radiographic Assessment Of Immediate Implant With Topical Vitamin D and Xenograft Mixture: A Randomized Controlled Study

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07065877
Acronym
vitD
Enrollment
20
Registered
2025-07-15
Start date
2025-07-20
Completion date
2027-01-01
Last updated
2025-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crestal Bone Loss

Brief summary

What is the difference between grafting the jumping gap upon using xenograft mixed with topical vitamin D clinically regarding crestal bone level and implant stability, radiographically regarding crestal bone level after implant insertion in the posterior region of mandible?

Detailed description

Effect of Vitamin D on Bone Regeneration .Vitamin D is known for its role in the skeletal system. Vit D deficiency is also widely researched for its effects on the healing of fractures, bone defects and osseointegration of implants. There are studies that investigated the effects of dietary supplementation with vitamin D to reduce vitamin D deficiency but increasing the serum level of this vitamin takes time therefore, an attempt has been made to combat the effect of vitamin D deficiency through topical application. up to the knowledge, upon search of literatures, there is not enough studies that correlate topical application of vitamin D with xenograft mixture as filling space material. this study is to Assess immediate implant with topical vitamin D and xenograft mixture clinically and Radiographically.

Interventions

DRUGvit D mixed with xenograft

Topical application of vitamin D solution mixed with xenograft in the jumping gap around immediate implant

DRUGonly xenograft without vit D

grafting the jumping gap with xenograft only around immediate implant

Sponsors

Suez Canal University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

vitamin D solution mixed with xenograft around immediate implant

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* The American Society of Anesthesiologist (ASA) I , II * Both Genders. 3- Patients having unrestorable tooth on the posterior mandibular region * Age\>20 * The patient who have complete their facial growth and teeth eruption * No bone disease or lesion in propose implant site

Exclusion criteria

* Poor oral hygiene patients and/or patients * Patients with active acute infection. * Patients with bad oral habits. * Pregnant or lactating women. * Heavy smokers. * Alcohol and drug addicts. * Diabetes disease

Design outcomes

Primary

MeasureTime frameDescription
clinically: A)Loss of crestal bone. B)Stability of implant. Radiographically: crestal bone loss by periapical radiograph in millimeters.clinically: Loss of crestal bone by periodontal prop assessed in millimeters in six months Stability of implant by OSTTEL assessed as ISQ values in six months crestal bone loss in millimeters will be one ,three months and six months.the loss of crestal bone after implant insertion using periodontal probe in millimeters. implant stability using OSTELL device. Postoperative follow up using periapical radiographs to evaluate crestal bone loss in millimeters will be after, one ,three months and six months by standardized parallel periapical digital technique radiograph .The radiographs will be done by using: The Kavo Scan eXamTM One and the Rinn extension cone paralleling (XCP)periapical film holder will be used to achieve standardization of digital radiographs.

Countries

Egypt

Contacts

Primary Contactmohamed elsaeed ibrahim, master
mohamedelsaeed683@gmail.com+201150315750
Backup ContactMohamed Nageh Gad El-Hak, Lecturer
+201002061808

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026